Mechanisms of Pregnancy Vascular Adaptations

Status Recruiting

Clinical Trial Summary

The investigators will collect omental tissue (research surgical excision) and placental tissue (standard of care clinical delivery) from both preeclamptic and non-preeclamptic women during their c-section and use these samples to study the blood vessels, specifically the expression/activation of the AT2R.

Clinical Trial Description

Trial Design: The study is a comparison of two cohorts, those with and without preeclampsia during pregnancy. The team plans to investigate role of FABP4, PFAS and AT2 in modulation of vascular function/dysfunction using vessels isolated from the omental biopsies. The investigators will examine for the evidence of fetal vascular dysfunction mediated by decreased expression of AT2 in preeclampsia using vessels isolated from the placentas. Study Population: The study will include pregnant women. The pregnant women will participate in the omental tissue collection, placenta collection, and the medical record review. The study is expects a maximum enrollment of 114 pregnant women. This is because 52 omental biopsies and 52 placentas are required to meet proposed statistical considerations. Participants have the option of providing just one or both of the specimens. There is a possibility as few as 52 participants could be enrolled and a maximum of 104 participants could be enrolled to meet this requirement. There is an additional 10 participants enrollment built into the enrollment number to allow for replacement of subjects based on lack of clinical data in some participants, failure of tissue viability and hence experiments, and thus a maximum of 114 (104+10) participants could be enrolled. This required enrollment (52) is divided into two cohorts based on the diagnosis of preeclampsia: 26 of each type of specimen in which the woman was diagnosed with preeclampsia during her pregnancy, and 26 of each type of specimen in which the woman was not diagnosed with preeclampsia during her pregnancy. Additionally, each cohort of 26 will be divided into two groups based on gender of the fetus, 13 male fetuses and 13 female fetuses ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03806283
Study type	Observational
Source	University of Wisconsin, Madison
Contact	Sharon E Blohowiak, MS
Phone	6084176957
Email	sblohowiak@wisc.edu
Status	Recruiting
Phase
Start date	November 20, 2018
Completion date	April 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05971407` - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Recruiting	`NCT04584632` - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery	N/A
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Completed	`NCT01684826` - X-ray Dose Reduction Study for Cardiac Angiography and Intervention	N/A
Completed	`NCT01417910` - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients	N/A
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Unknown status	`NCT01748383` - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)	Phase 2
Recruiting	`NCT05907564` - Aventus Thrombectomy System Pulmonary Embolism Clinical Study	N/A
Recruiting	`NCT03732612` - Inflammation in Vascular Disease
Completed	`NCT00000614` - Prevention of Recurrent Venous Thromboembolism (PREVENT)	Phase 3
Completed	`NCT00000530` - Raynaud's Treatment Study (RTS)	Phase 3
Completed	`NCT00000479` - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer	Phase 3
Completed	`NCT00000539` - Arterial Disease Multifactorial Intervention Trial (ADMIT)	Phase 3
Completed	`NCT00000474` - Prevention and Treatment of Hypertension Study (PATHS)	Phase 3
Completed	`NCT00000528` - Trials of Hypertension Prevention (TOHP)	Phase 3
Completed	`NCT00000509` - Potassium and Sodium to Control Blood Pressure in Hypertensives	Phase 3
Completed	`NCT00000501` - Hypertension Prevention Trial (HPT) Feasibility Study	Phase 2
Completed	`NCT00000499` - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.